Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16109926 | 0.90 | BACE1 (1.00) | BACE1CTSD | |
| SCHEMBL16109689 | 0.90 | BACE1 (1.00) | BACE1CTSD | |
| SCHEMBL14823722 | 0.88 | BACE1 (1.00) | BACE1CTSD | |
| SCHEMBL16109657 | 0.88 | BACE1 (1.00) | BACE1CTSD | |
| SCHEMBL14808739 | 0.85 | BACE1 (0.74) | BACE1 | |
| SCHEMBL16108935 | 0.82 | BACE1 (1.00) | BACE1CTSD | |
| SCHEMBL16109591 | 0.81 | BACE1 (1.00) | BACE1CTSD | |
| SCHEMBL16109923 | 0.80 | BACE1 (1.00) | BACE1 | |
| SCHEMBL16109447 | 0.79 | BACE1 (1.00) | BACE1CTSD | |
| SCHEMBL16109567 | 0.79 | BACE1 (1.00) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159818-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2016-06-09 | — | — | US | claimed |
| US-9296759-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | claimed |
| US-20140296226-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. | 2014-10-02 | — | — | US | claimed |
| US-9777019-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160159818-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9296759-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140296226-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296226-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, APP, BACE2 | BACE1 1/4885CTSD 2116/4885 |
| US-20160159818-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, APP, BACE2 | BACE1 1/4885CTSD 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.